Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations
ES Kim, B Melosky, K Park, N Yamamoto… - Future …, 2021 - Taylor & Francis
Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
N Magios, F Bozorgmehr, AL Volckmar… - Therapeutic …, 2021 - journals.sagepub.com
Background: Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
[HTML][HTML] Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
AS Pal, M Bains, A Agredo, AL Kasinski - Biochemical pharmacology, 2021 - Elsevier
Lung cancer is the leading cause of cancer-related deaths, demanding improvement in
current treatment modalities to reduce the mortality rates. Lung cancer is divided into two …
current treatment modalities to reduce the mortality rates. Lung cancer is divided into two …
Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or …
T Nishimura, T Okano, M Naito, S Iwanaka… - Thoracic …, 2021 - Wiley Online Library
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in
approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung …
approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung …
Resumen de tesis. The MEK5/ERK5 pathway in lung and ovarian cancer
A Sánchez Fernández - 2021 - gredos.usal.es
[EN] There is an obvious clinical need for unveiling novel pathophysiological mechanisms
underlying lung and ovarian tumors that could foster the development of new targeted …
underlying lung and ovarian tumors that could foster the development of new targeted …
[PDF][PDF] Ο ρόλος και η κλινική χρησιμότητα της υγρής βιοψίας στον μη μικροκυτταρικό καρκίνο του πνεύμονα
Π Καλησπεράτη - 2021 - olympias.lib.uoi.gr
Η νόσος του καρκίνου αποτελεί ένα από τα σημαντικότερα προβλήματα δημόσιας υγείας και
παρά την πρόοδο της ιατρικής επιστήμης εξακολουθεί να είναι μία από τις σπουδαιότερες …
παρά την πρόοδο της ιατρικής επιστήμης εξακολουθεί να είναι μία από τις σπουδαιότερες …